10.3389/fphar.2024.1438926 [DOI] [PMC free article] [PubMed] [Google Scholar] Lin T
Understanding these interactions is essential for optimising treatment outcomes and preventing deficiency in at-risk individuals
The cornerstone of plateau management remains optimisation of diet and physical activity, as GLP-1 receptor agonists work synergistically with behavioural interventions
For weight loss, there are several Zepbound alternatives, including other GLP-1s that Aetna may cover, such as Saxenda or Wegovy
Collectively, these findings demonstrate that SLE is characterized by mTOR pathway hyperactivation and distinct T cell metabolic reprogramming favoring glycolysis and FAS, which disrupts Th17/Treg balance and drives autoimmunity, positioning metabolic intervention as a viable treatment strategy
However, its important to remember that obesity is a chronic disease, and these are long-term treatments that may not be covered by insurance